Kidney Int Rep
chronic hepatitis C; chronic kidney disease; direct-acting antiviral; hepatitis C virus
Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment.
Methods: We performed a
Results: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547), and 97% (32/33), respectively, with OBV/PTV/r + DSV; and, 96% (1172/1221), 96% (1208/1254), and 93% (55/59), respectively, with OBV/PTV/r + DSV + RBV. Overall rates of serious AEs and renal AEs were 3% (95/3567) and 2% (56/3567), respectively. Factors associated with an eGFR increase of ≥10 ml/min per 1.73 m
Conclusion: OBV/PTV/r + DSV ± RBV achieved high SVR rates and was generally well tolerated irrespective of CKD stage.
Kidney & Diabetes
Bernstein, David E; Tran, Albert; Martin, Paul; Kowdley, Kris V; Bourliere, Marc; Sulkowski, Mark S; Pockros, Paul J; Renjifo, Boris; Wang, Deli; Shuster, Diana L; Cohen, Daniel E; and Jacobson, Ira M, "Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease." (2019). Articles, Abstracts, and Reports. 1137.